Buy BPC-157 10mg

BPC-157 10mg For Sale 

BPC-157 (Body Protective Compound-157) is an investigational synthetic pentadecapeptide composed of 15 amino acids (GEPPPGKPADDAGLV) with a molecular weight of approximately 1,419 Da. The peptide was first described in the scientific literature in the early 1990s as part of research on protective compounds associated with gastric proteins. Although its sequence originates from investigations of proteins found in human gastric juice, the BPC-157 used in laboratory settings is a synthetically manufactured peptide produced for scientific research.

Experimental studies have reported that BPC-157 remains stable under acidic conditions, a characteristic that distinguishes it from several endogenous growth factors that rapidly degrade in gastric environments. This stability has made the peptide a frequent subject of research involving tissue repair, angiogenesis, gastrointestinal biology, and cellular signaling. However, the current evidence base consists primarily of in vitro experiments and animal studies, while well-designed human clinical research remains limited.

Over the past three decades, researchers have explored the biological activity of BPC-157 across multiple experimental models involving the musculoskeletal, gastrointestinal, vascular, nervous, and ocular systems. Published studies have investigated its interactions with angiogenic pathways, nitric oxide signaling, inflammatory mediators, and cellular repair mechanisms. While these findings have generated considerable scientific interest, they should be interpreted within the context of preclinical research, as BPC-157 has not been approved by the U.S. Food and Drug Administration (FDA) or other major regulatory authorities for therapeutic use in humans.

Molecular Features of BPC-157

BPC-157 represents a synthetic pentadecapeptide consisting of 15 amino acids with the structure GEPPPGKPADDAGLV and a molecular mass of about 1,419 Da. The first record regarding the peptide appeared during experiments with gastric proteins, and now it has become a commonly investigated investigational peptide used in laboratory conditions.

According to experimental studies, BPC-157 demonstrates acid stability that is not inherent to a number of growth factors being quickly degraded in an environment of the stomach. Such a feature has made the peptide a commonly studied one in the context of tissue regeneration, angiogenesis, and signaling. However, most of the available studies have been in vitro or animal studies and lack the presence of large-scale human clinical trials.

Mechanism of Action

Although the exact mode of action of BPC-157 has not yet been defined, preclinical research implies that BPC-157 affects various physiological processes related to:

• Tissue repair
• Functioning of the vasculature 
• Cell signaling 

Most data on this topic come from experimental investigations performed in vitro or using animals and have not been verified in clinical trials involving many human subjects.

Experimental research has found that BPC-157 could stimulate the process of angiogenesis by means of its effects on the VEGFR2-Akt-eNOS signaling pathway. 

Other modes of action identified through experimental studies include BPC-157-induced modulation of nitric oxide signaling, activation of FAK-paxillin and ERK1/2 pathways, as well as stimulation of fibroblast migration and collagen production. These modes of action of BPC-157 have supposedly contributed to the positive results obtained in preclinical models.

BPC-157 has also been shown to affect the expression of various cytokines and growth factors in connection with the functioning of the inflammatory pathways. Although this observation has provided some information regarding the biological activity of BPC-157, more clinical research is necessary in order to evaluate its significance in humans.

Preclinical Research

BPC-157 has been investigated in a variety of in vitro and animal models. While the results are still preliminary, there are published studies that indicate the peptide can affect a number of biological processes that are important in tissue repair, vascular function, and cellular signaling. Subjects of enquiry include:

• Muscle and Skeletal: Animal studies show better healing of tendons, ligaments, muscles, and bone. Research also has shown increased activity of fibroblasts and collagen organization and tendon-to-bone integration after injury.
• Gastrointestinal Research: Since BPC-157 was discovered as a result of research on gastrointestinal proteins, many studies have been conducted on the influence of BPC-157 on gastrointestinal tissues. Protective effects have been reported in experimental models of gastric injury and intestinal healing, inflammatory bowel disease, and surgical anastomosis.
• Neurological Research: Preclinical models have been studied with BPC-157 in reference to dopamine, serotonin, glutamate, and nitric oxide signaling. Its activity has also been studied in animal models with disease-like conditions that mimic neurodegenerative disorders, such as Parkinson’s disease and Alzheimer’s disease.
• Vascular Research: Experimental results indicate that the effect of BPC-157 can be pro-angiogenic and beneficial for endothelial function via mechanisms related to VEGFR2 and nitric oxide signaling. Based on these observations, researchers have studied its function in tissue repair and vascular remodeling.
• Ocular Research: Animal research has investigated BPC-157 in models of corneal injury, with researchers reporting “enhanced” corneal healing, maintaining corneal transparency, and normalizing elevated intraocular pressure in experimental settings.

These results have led to a lot of scientific interest, but should be used in the context of preclinical research. Further well-designed human clinical trials are required to assess the safety, efficacy, and clinical relevance of the peptide.

Pharmacokinetic Profile 

Currently, there are very few pharmacokinetic studies regarding BPC-157, and results of the existing ones also vary significantly according to experimental models and modes of administration. At the same time, current data indicate that the peptide is metabolized mainly in the liver and excreted via renal clearance, yet further studies are needed to confirm and describe pharmacokinetic parameters completely.

According to preclinical research, the peptide displays prolonged tissue retention after both intravenous and oral administration in animal models. Still, estimated values of half-life periods also vary significantly between different studies, and thus the exact pharmacokinetics of the substance cannot be determined at present.

According to preclinical binding research, BPC-157 does not affect any of the major neurotransmitter receptors, such as adrenergic, dopaminergic, serotonergic, muscarinic, histaminergic, and adenosine receptors. Moreover, preclinical research has found no increase in activity of hepatic cytochrome P450 enzymes, but further clinical confirmation of these findings is required.

Human Research

Human studies on BPC-157 are scarce, and there is not enough information to determine the safety and efficacy of this substance. The majority of research studies were conducted as pre-clinical tests, and the clinical studies included rather small samples of subjects.

The initial research on BPC-157 was performed under the scientific name PL 14736 to evaluate the substance for inflammatory bowel disease. Besides, retrospective research on intra-articular injections of BPC-157 for the treatment of chronic knee pain has shown the improvement of the condition among the participants. Nonetheless, the mentioned research has several drawbacks, including small sample size and lack of follow-up, which make it impossible to reach clear conclusions on the clinical effects of the substance.

Research Disclaimer

Further scientific research on the substance is needed at the present time; however, larger randomized controlled trials are required to investigate the pharmacology and possible therapeutic uses of the substance in humans.

FAQs

1. What is BPC-157, and where does it originate from?

BPC-157 is a laboratory-synthesized peptide containing 15 amino acids (GEPPPGKPADDAGLV). It is an active fragment of a naturally occurring protein in human gastric juice. Introduced in 1993, BPC-157 is characterized by high stability in the gastric juice environment.

2. What are the main modes of action of BPC-157?

The BPC-157 mode of action is based on several mechanisms, such as induction of angiogenesis through the VEGFR2-Akt-eNOS signaling pathway, modulation of the nitric oxide system in two directions, growth hormone receptor upregulation and FAK-paxillin signaling, and reduction of inflammatory cytokines. These mechanisms play a key role in tissue regeneration and repair under experimental conditions.

3. What musculoskeletal indications are studied?

There is considerable evidence from preclinical investigations related to the use of BPC-157 for tendon/ligament regeneration, muscle repair, and bone regeneration. Animal studies have shown positive results in terms of functional, morphological, and biomechanical improvement in the case of injury to muscles, tendons, ligaments, and bones. The systematic review identified 35 preclinical studies in this field.

References

1. Sikiric P, Hahm KB, Blagaic AB, et al. The stable gastric pentadecapeptide BPC 157: From basic research to biological activity and therapeutic potential. Pharmaceuticals (Basel). 2024;17(4):461. doi:10.3390/ph17040461
2. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157 and its role in Robert’s cytoprotection and adaptive organ protection. Gut and Liver. 2020;14(2):153-167. doi:10.5009/gnl18490
3. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157 as a therapy and safety key: A pleiotropic effect controlling angiogenesis and the nitric oxide system. Pharmaceuticals (Basel). 2025;18(6):928.
4. Perovic D, et al. From regeneration to analgesia: The role of BPC-157 in tissue repair and pain management. International Journal of Molecular Sciences. 2026;27(6):2876.
5. Sikiric P, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL 10, PLD-116, PL 14736). Inflammopharmacology. 2006;14(5-6):214-221.
6. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. Sports Health. 2025.
7. National Center for Biotechnology Information. PubMed database. Accessed July 2026.
8. National Center for Biotechnology Information. PubMed Central (PMC). Accessed July 2026.
9. U.S. Food and Drug Administration. FDA Drug Database. Accessed July 2026.
10. National Institutes of Health. Office of Dietary Supplements and biomedical literature resources. Accessed July 2026.